Paliperidone

🧮 Dose calculator

Schizophrenia · Regimen source: FDA Invega · 2.1

• • Increase above 6 mg only after reassessment, at >5-day intervals, in 3 mg steps. FDA Invega · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Invega · 8.1

  “Risk Summary Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see Clinical Considerations ) .”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Invega · 8.2

  “Risk Summary Limited data from published literature report the presence of paliperidone in human breast milk.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Invega · 8.4

  “Safety and effectiveness of INVEGA in the treatment of schizophrenia were evaluated in 150 adolescent subjects 12–17 years of age with schizophrenia who received INVEGA in the dose range of 1.5 mg to 12 mg/day in a 6-week, double-blind, placebo-controlled trial.”

• 👴 Older adultsDangerous / avoid

  Label: serious warning or avoid in older adults. FDA Invega · Boxed Warning

  “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Invega · 8.3

  “Infertility Females Based on the pharmacologic action of paliperidone (D 2 receptor antagonism), treatment with INVEGA may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential [see Warnings and Precautions (5.7) ].”